Literature DB >> 20431069

Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice.

Geoffrey Schultz1, Maureen M Tedesco, Eiketsu Sho, Toshihiko Nishimura, Shadi Sharif, Xiaoyan Du, Timothy Myles, John Morser, Ronald L Dalman, Lawrence L K Leung.   

Abstract

OBJECTIVE: To determine whether procarboxypeptidase B (pCPB)(-/-) mice are susceptible to accelerated abdominal aortic aneurysm (AAA) development secondary to unregulated OPN-mediated mural inflammation in the absence of CPB inhibition. METHODS AND
RESULTS: Thrombin/thrombomodulin cleaves thrombin-activatable pCPB or thrombin-activatable fibrinolysis inhibitor, activating CPB, which inhibits the generation of plasmin and inactivates proinflammatory mediators (complement C5a and thrombin-cleaved osteopontin [OPN]). Apolipoprotein E(-/-)OPN(-/-) mice are protected from experimental AAA formation. Murine AAAs were created via intra-aortic porcine pancreatic elastase (PPE) infusion. Increased mortality secondary to AAA rupture was observed in pCPB(-/-) mice at the standard PPE dose. At reduced doses of PPE, pCPB(-/-) mice developed larger AAAs than wild-type controls (1.01+/-0.27 versus 0.68+/-0.05 mm; P=0.02 [mean+/-SD]). C5(-/-) and OPN(-/-) mice were not protected against AAA development. Treatment with tranexamic acid inhibited plasmin generation and abrogated enhanced AAA progression in pCPB(-/-) mice.
CONCLUSIONS: This study establishes the role of CPB in experimental AAA disease, indicating that CPB has a broad anti-inflammatory role in vivo. Enhanced AAA formation in the PPE model is the result of increased plasmin generation, not unregulated C5a- or OPN-mediated mural inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431069     DOI: 10.1161/ATVBAHA.109.202259

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  12 in total

1.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

2.  Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.

Authors:  Z Shao; T Nishimura; L L K Leung; J Morser
Journal:  J Thromb Haemost       Date:  2015-05-10       Impact factor: 5.824

3.  Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

Authors:  Jason J Song; Inyong Hwang; Kyung H Cho; Michael A Garcia; Arthur J Kim; Tiffany H Wang; Tamsin M Lindstrom; Annette T Lee; Toshihiko Nishimura; Lei Zhao; John Morser; Michael Nesheim; Stuart B Goodman; David M Lee; S Louis Bridges; Peter K Gregersen; Lawrence L Leung; William H Robinson
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.

Authors:  Monica M Dua; Noriyuki Miyama; Junya Azuma; Geoffrey M Schultz; Mien Sho; John Morser; Ronald L Dalman
Journal:  Surgery       Date:  2010-06-19       Impact factor: 3.982

5.  Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression.

Authors:  Yasunori Iida; Baohui Xu; Haojun Xuan; Keith J Glover; Hiroki Tanaka; Xiaolei Hu; Naoki Fujimura; Wei Wang; Joshua R Schultz; Court R Turner; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

Review 6.  Novel mechanisms of abdominal aortic aneurysms.

Authors:  Hong Lu; Debra L Rateri; Dennis Bruemmer; Lisa A Cassis; Alan Daugherty
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 7.  Carboxypeptidases in disease: insights from peptidomic studies.

Authors:  Matthew R Sapio; Lloyd D Fricker
Journal:  Proteomics Clin Appl       Date:  2014-03-24       Impact factor: 3.494

Review 8.  Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms.

Authors:  Jinyun Shi; Jia Guo; Zhidong Li; Baohui Xu; Masaaki Miyata
Journal:  J Atheroscler Thromb       Date:  2021-03-06       Impact factor: 4.928

Review 9.  Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?

Authors:  Scott J Cameron; Hannah M Russell; A Phillip Owens
Journal:  Blood       Date:  2018-09-18       Impact factor: 25.476

Review 10.  Recent Advances in the Development of Experimental Animal Models Mimicking Human Aortic Aneurysms.

Authors:  Young Sun Yoo; Hyung Sub Park; Geum Hee Choi; Taeseung Lee
Journal:  Vasc Specialist Int       Date:  2015-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.